Product Images Venlafaxine Hydrochloride

This is a description of Venlafaxine HCI extended-release capsules, USP. The medication comes in 50 capsules (5 x 10) unit dose packaging, with each capsule containing 0.75g of Venlafaxine HCI extended-release, which is an antidepressant medication. The recommended dosage of the medication is provided in the accompanying prescription information and it should be stored at 20°C to 25°C (68°F to 77°F). The medication is manufactured by Avkare and should be dispensed with the medication guide provided to each patient.*

This is a prescription medication for Venlafaxine HCI. It comes in the form of extended-release capsules with 50 capsules per pack, each containing 75mg of Venlafaxine HCI. The dosage should be based on the accompanying prescribing information and the medication guide provided separately for each patient. It should be stored at a controlled room temperature between 20-25°C (68°-71°F). The manufacturer is Avkare.*

This is a description of Venlafaxine HCI extended-release capsules, which come in the strength of 150 mg. The capsules are packaged in unit doses of 50 per container and are only available with a prescription. The medication guide should be provided separately to each patient, and the usual dosage should be followed according to the accompanying prescribing information. The medication must be stored at controlled room temperature and is manufactured for AVKARE.*

This text seems to describe a report on an interaction drug identified as "Incrpzoa s" and an analyte. It provides information on PK Fold Change and 90% C1 recommendation for "Mo dose sdusmers" and lists hypertension, sedentary behavior and hypothalamic dysfunction as potential conditions related to the interaction. However, the text is incomplete and difficult to understand out of context.*

This appears to be a table showing information about a drug called Matoprotol and its interactions with other drugs. The column labeled "Analyte PKFold Change and 90% CRecommendation" may provide information on the recommended dosage adjustments for Matoprotol based on the levels of other drugs in the body. However, the text is not entirely clear and some characters are unreadable, making it difficult to fully understand the table. Therefore, more information could not be provided.*

This text is not-available.*